云顶新耀(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01952 云顶新耀

未开盘 09-24 16:08:31

27.500

-1.480

-5.11%

最高29.260	最低26.960	成交量497.95万
今开29.260	昨收28.980	日振幅7.94%
总市值97.35亿	流通市值97.35亿	总股本3.54亿
成交额1.37亿	换手率1.41%	流通股本3.54亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01952","market":"HK","secType":"STK","nameCN":"云顶新耀","latestPrice":27.5,"timestamp":1790237311004,"preClose":28.98,"halted":0,"volume":4979500,"delay":0,"changeRate":-0.0510697032436163,"floatShares":354000000,"shares":354000000,"eps":-0.89,"marketStatus":"未开盘","change":-1.48,"latestTime":"09-24 16:08:31","open":29.26,"high":29.26,"low":26.96,"amount":137407775,"amplitude":0.079365,"askPrice":27.52,"askSize":500,"bidPrice":27.5,"bidSize":8500,"shortable":3,"etf":0,"ttmEps":-0.175,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790299800000},"marketStatusCode":0,"adr":0,"listingDate":1602172800000,"exchange":"SEHK","adjPreClose":28.98,"openAndCloseTimeList":[[1790213400000,1790222400000],[1790226000000,1790236800000]],"volumeRatio":0.780153,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01952/tweets","defaultTab":"tweets","newsList":[{"id":"1150198423","title":"异动解读｜云顶新耀盘中下跌5.04%，报27.52港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1150198423","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150198423?lang=zh_cn&edition=full","pubTime":"2026-09-24 10:15","pubTimestamp":1790216138,"startTime":"0","endTime":"0","summary":"9月24日，云顶新耀盘中下跌5.04%，报27.52港元/股，成交额6549.15万港元。云顶新耀所在的生物科技行业整体承压，个股中，康方生物跌3.64%，信达生物跌3.67%，百济神州跌1.56%，荣昌生物跌5.77%，三生制药跌3.88%。云顶新耀是一家主要从事创新药及疫苗研发、临床开发、制造及商业化的生物制药公司，已建立跨肾病、抗感染及自身免疫性疾病的产品管线，核心产品包括用于肾病治疗的耐赋康及用于治疗多重耐药菌感染的依嘉等。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172059320","title":"异动解读｜云顶新耀盘中上涨5.23%，维适平境内生产注册申请获受理叠加多重利好共振","url":"https://stock-news.laohu8.com/highlight/detail?id=1172059320","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172059320?lang=zh_cn&edition=full","pubTime":"2026-09-23 10:42","pubTimestamp":1790131359,"startTime":"0","endTime":"0","summary":"9月23日，云顶新耀盘中上涨5.23%，报30.2港元，成交额8867.81万港元。消息面上，公司核心产品维适平由境外转移至境内生产的药品上市注册申请近日获国家药监局受理，并纳入优先审评审批程序，本地化生产有望降低供应链风险并改善成本结构。此外，公司心血管领域首款创新药星必妥于9月初获NMPA批准上市，产品管线持续丰富；董事会主席吴以芳近期连续增持合计2.8万股，释放管理层信心。公司上半年收入11.48亿元，同比增长157%，经调整利润实现扭亏为盈，多重利好共振提振市场情绪。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"云顶新耀上涨，维适平获批受理","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176073645","title":"异动解读｜云顶新耀盘中上涨5.8%，维适平境内生产上市注册申请获受理并纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=1176073645","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176073645?lang=zh_cn&edition=full","pubTime":"2026-09-21 09:43","pubTimestamp":1789955030,"startTime":"0","endTime":"0","summary":"9月21日，云顶新耀盘中上涨5.8%，报29.18港元，成交额5120.3万港元。消息面上，公司核心产品维适平由境外转移至境内生产的药品上市注册申请已获国家药监局受理，并纳入优先审评审批程序，本地化生产有望降低供应链风险并改善成本结构。此外，公司心血管领域首款创新药星必妥于9月初获NMPA批准上市，产品管线持续丰富。公司上半年收入11.48亿元，同比增长157%，经调整利润实现扭亏为盈，董事会主席近期亦进行增持操作，多重利好共振提振市场情绪。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"云顶新耀上涨，维适平国产化获批提速","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133345178","title":"异动解读｜云顶新耀盘中上涨5.24%，维适平境内生产上市注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1133345178","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133345178?lang=zh_cn&edition=full","pubTime":"2026-09-18 09:53","pubTimestamp":1789696397,"startTime":"0","endTime":"0","summary":"9月18日，云顶新耀盘中上涨5.24%，报27.72港元，成交额6589.46万港元。消息面上，公司核心产品维适平由境外转移至境内生产的药品上市注册申请已获受理，生产本地化有望降低供应链风险并改善成本结构。公司上半年收入11.48亿元，同比增长157%，核心产品耐赋康纯销同比增长94%，经调整利润实现扭亏为盈。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"云顶新耀盘中上涨，维适平国产化获批受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668158916","title":"港股异动 | 云顶新耀(01952.HK)早盘涨超5% 维适平®由境外转移至境内生产的药品上市注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2668158916","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668158916?lang=zh_cn&edition=full","pubTime":"2026-09-18 09:34","pubTimestamp":1789695261,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","01952","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667667063","title":"董事会主席吴以芳增持云顶新耀(01952)8000股 每股作价26.9港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667667063","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667667063?lang=zh_cn&edition=full","pubTime":"2026-09-14 19:08","pubTimestamp":1789384113,"startTime":"0","endTime":"0","summary":"9月11日，董事会主席吴以芳增持云顶新耀(01952)8000股，每股作价26.9港元，总金额为21.52万港元。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260914/20260914190902_80115.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260914/20260914190902_80115.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495795.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["01952","EWH","BK1583","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667860876","title":"云顶新耀获董事会主席吴以芳增持2万股 每股作价约28.71港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667860876","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667860876?lang=zh_cn&edition=full","pubTime":"2026-09-13 13:53","pubTimestamp":1789278780,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端香港联交所最新数据显示，9月10日，董事会主席吴以芳增持云顶新耀（01952）2万股，每股作价28.7065港元，总金额约为57.41万港元。增持后最新持股数目约为218.02万股，最新持股比例为0.62%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-09-13/doc-inirscya7885197.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EWH","01952","BK1583","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666524123","title":"董事会主席吴以芳增持云顶新耀(01952)2万股 每股作价约28.71港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666524123","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666524123?lang=zh_cn&edition=full","pubTime":"2026-09-11 19:22","pubTimestamp":1789125762,"startTime":"0","endTime":"0","summary":"9月10日，董事会主席吴以芳增持云顶新耀(01952)2万股，每股作价28.7065港元，总金额约为57.41万港元。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260911/20260911192313_55668.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260911/20260911192313_55668.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495163.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["01952","BK1583","BK1574","BK1161","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167075914","title":"云顶新耀：吴以芳增持，好仓比例升至0.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=1167075914","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167075914?lang=zh_cn&edition=full","pubTime":"2026-09-11 17:51","pubTimestamp":1789120264,"startTime":"0","endTime":"0","summary":"吴以芳于2026年9月10日以每股均价28.7065港元买入云顶新耀股份2.00万股，涉资约57.41万港元。吴以芳此次增持前持有云顶新耀好仓216.02万股，占比0.61%；增持后持股量为218.02万股，好仓比例升至0.62%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116751111","title":"异动解读｜云顶新耀盘中下跌5.39%，海森战略合作关联交易引发市场疑虑叠加利好兑现抛压延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1116751111","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116751111?lang=zh_cn&edition=full","pubTime":"2026-09-11 10:15","pubTimestamp":1789092942,"startTime":"0","endTime":"0","summary":"9月11日，云顶新耀盘中下跌5.39%，报27.02港元，成交额5103.65万港元，连续第四个交易日回调。由于海森为公司关联方，市场对交易定价公允性、账期风险承担及中小股东利益保护存在较大顾虑，此前公司拟收购海森相关股权时即曾引发争议。同时，星必妥获NMPA批准的利好自9月8日大涨后持续兑现，抛压未尽。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"云顶新耀持续走弱，关联交易引发市场疑虑","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109716349","title":"异动解读｜云顶新耀盘中下跌5.38%，星必妥获批利好持续兑现叠加板块走弱延续回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1109716349","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109716349?lang=zh_cn&edition=full","pubTime":"2026-09-10 09:35","pubTimestamp":1789004159,"startTime":"0","endTime":"0","summary":"9月10日，云顶新耀盘中下跌5.38%，报29.52港元，成交额2586.4万港元，延续近两日回调走势。消息面上，公司9月3日宣布星必妥获中国NMPA批准上市，用于治疗成人PSVT急性发作，系30余年来首款且唯一获批的创新疗法。该利好驱动9月8日股价大涨超5%后，市场进入典型的利好兑现抛压阶段，9月9日已回吐前日涨幅跌超5%，今日跌势延续。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"云顶新耀回调延续，星必妥利好兑现后承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666559836","title":"星必妥获批填补PSVT院外“应急自救”空白，云顶新耀3.0增长逻辑渐清晰","url":"https://stock-news.laohu8.com/highlight/detail?id=2666559836","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666559836?lang=zh_cn&edition=full","pubTime":"2026-09-10 09:00","pubTimestamp":1789002017,"startTime":"0","endTime":"0","summary":"云顶新耀在心血管领域，拿下了一张关键“王牌”。9月3日，云顶新耀宣布，中国国家药品监督管理局（NMPA）已批准星必妥?（艾曲帕米鼻喷雾剂）的新药上市许可申请（NDA），用于治疗成人阵发性室上性心动过速（PSVT）急性症状发作，转复为窦性心律。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609103870101240.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609103870101240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1583","01952","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163368787","title":"云顶新耀(01952)拟与海森签订战略合作框架协议　设定2026—2028年最高30.76亿元采购上限","url":"https://stock-news.laohu8.com/highlight/detail?id=1163368787","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163368787?lang=zh_cn&edition=full","pubTime":"2026-09-09 20:15","pubTimestamp":1788956136,"startTime":"0","endTime":"0","summary":"云顶新耀有限公司9月9日公告，于2026年9月9日旗下全资附属公司与海森生物医药有限公司签订战略合作框架协议，拟就产品在中国的供应、分销、制造及商业化开展合作。协议生效期至2028年12月31日，期满后如无异议自动续期三年。现有商业化服务协议继续有效，海森集团在2026、2027及2028年度向云顶新耀支付的服务费上限分别为5.60亿元、6.16亿元及6.77亿元，相关金额不计入上述采购年度上限。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666538265","title":"云顶新耀(01952.HK)与海森订立战略合作框架协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538265","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666538265?lang=zh_cn&edition=full","pubTime":"2026-09-09 20:13","pubTimestamp":1788956015,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","01952","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166436318","title":"异动解读｜云顶新耀盘中下跌5.02%，星必妥获批利好兑现后股价回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1166436318","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166436318?lang=zh_cn&edition=full","pubTime":"2026-09-09 10:09","pubTimestamp":1788919796,"startTime":"0","endTime":"0","summary":"9月9日，云顶新耀盘中下跌5.02%，报31.38港元，成交额9034.67万港元。消息面上，公司9月3日宣布星必妥（艾曲帕米鼻喷雾剂）获中国NMPA批准上市，用于治疗成人阵发性室上性心动过速（PSVT）急性发作，系30余年来首款且唯一获批用于该适应症的创新疗法。受此利好驱动，前一交易日股价大涨5.56%。今日股价回吐前一日涨幅，呈现典型的利好兑现后回调走势。与此同时，生物科技板块整体承压，百济神州跌1.97%，康希诺生物跌2.71%，板块弱势对个股亦形成拖累。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"云顶新耀回调，星必妥获批利好兑现","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136255696","title":"港股异动｜生物技术板块午后拉升，剂泰科技涨近13%，百奥赛图涨超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1136255696","media":"老虎快讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136255696?lang=zh_cn&edition=full","pubTime":"2026-09-08 13:34","pubTimestamp":1788845673,"startTime":"0","endTime":"0","summary":"港股生物技术板块午后拉升，剂泰科技涨近13%，百奥赛图涨超8%，云顶新耀、基石药业涨超4%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07666","02315","01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113703587","title":"港股生物医药股午后走强，剂泰科技-P涨近15%，百奥赛图-B、金斯瑞生物科技涨近10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1113703587","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113703587?lang=zh_cn&edition=full","pubTime":"2026-09-08 13:33","pubTimestamp":1788845625,"startTime":"0","endTime":"0","summary":"9月8日，港股$生物(000504)$医药股午后走强，$剂泰科技-P(07666)$涨近15%，$百奥赛图-B(02315)$、$金斯瑞生物科技(01548)$涨近10%，$泰格医药(03347)$、$康希诺生物(06185)$、$云顶新耀(01952)$涨超5%。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","HK0000306685.HKD","BK1191","BK1583","HK0000320223.HKD","XBI","01952","02315","BK1515","BK4585","BK1576","BK4581","06185","KCAI","BK1574","03347","BK0216","161726","HK0000306701.USD","01548","399441","BK1161","HK0000320264.USD","688796","BK4588","07666","VXUS","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665412573","title":"港股异动 | 云顶新耀(01952.HK)早盘涨超5% 星必妥PSVT适应症新药上市申请在华获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2665412573","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665412573?lang=zh_cn&edition=full","pubTime":"2026-09-08 11:53","pubTimestamp":1788839607,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK1161","01952","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108592735","title":"云顶新耀更新2026年8月股份变动月报表，股本增至354,077,331股","url":"https://stock-news.laohu8.com/highlight/detail?id=1108592735","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108592735?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:41","pubTimestamp":1788511279,"startTime":"0","endTime":"0","summary":"云顶新耀有限公司于2026年9月4日发布2026年8月股份变动月报表，披露了截至2026年8月31日的股本及股份变动。公司已发行普通股由上月底的353,839,022股增至354,077,331股，当月净增加238,309股，未持有库存股份。公司确认截至报告期末，已满足相关公众持股量要求。根据公告，当月主要的股份变动来自购股权计划的行使，其中“首次公开发售后购股权计划”行使238,309股，产生总额5,211,879.97港元认股款。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664238859","title":"【券商聚焦】交银国际：医药行业收入稳健增长 多重利好推动盈利表现显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2664238859","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664238859?lang=zh_cn&edition=full","pubTime":"2026-09-04 09:00","pubTimestamp":1788483634,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，1H26港股/A股医药行业整体收入增长4.7%/3.2%。创新药产业链增速领跑行业，服务板块复苏：1）港股/A股CXO收入整体增长29.2%/25.3%，（扣非）净利润增长23.4%/67.6%，在各子板块中增速最快，行业整体景气度和订单需求处于高位。2）核心成药板块收入增长17.8%/3.4%、利润增长62.7%/35.0%。其中生物药增速远超化药，在板块收入中的占比也进一步提升。3）医院、器械、诊断、疫苗等板块业绩有复苏趋势。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990646","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03759","02273","02268","01177","KCE","IE00B5MMRT66.SGD","02269","01530","02162","HK0000320264.USD","LU0039217434.USD","06160","KURE","LU1251922891.USD","06078","SG9999004220.SGD","00013","01548","06990","HK0000306685.HKD","09996","BK1161","09966","03329","BK1209","02096","LU0856984785.SGD","LU1152091168.USD","IE00B0JY6N72.USD","IE00B543WZ88.USD","01801","01952","01951","LU0315179316.USD","LU0348783233.USD","02596","06821","06996","03692","01093","LU2543165471.USD","LU1880383366.USD","BK1515","LU0327786744.USD","LU0588546209.SGD","BK1589","09926","01276","LU1242518857.USD","LU0307460666.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.everestmedicines.com","stockEarnings":[{"period":"1week","weight":0.044},{"period":"1month","weight":-0.2535},{"period":"3month","weight":0.1894},{"period":"6month","weight":-0.2801},{"period":"1year","weight":-0.4973},{"period":"ytd","weight":-0.2564}],"compareEarnings":[{"period":"1week","weight":0.0064},{"period":"1month","weight":-0.0294},{"period":"3month","weight":0.0922},{"period":"6month","weight":-0.0076},{"period":"1year","weight":-0.0663},{"period":"ytd","weight":-0.0339}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"云顶新耀有限公司是一家主要从事创新药及疫苗研发、临床开发、制造及商业化的生物制药公司。该公司已建立跨肾病、抗感染及自身免疫性疾病的产品管线。该公司的产品管线包括用于肾病治疗领域的耐赋康（TARPEYO）、用于治疗包括临床常见的革兰氏阴性菌、革兰氏阳性菌、厌氧菌等多重耐药菌的感染的依嘉（依拉环素）等产品。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.01035},{"month":2,"riseRate":0.333333,"avgChangeRate":0.039331},{"month":3,"riseRate":0.333333,"avgChangeRate":0.002002},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.092533},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.045773},{"month":6,"riseRate":0.666667,"avgChangeRate":0.224714},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.090363},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.046758},{"month":9,"riseRate":0.5,"avgChangeRate":0.012915},{"month":10,"riseRate":0.4,"avgChangeRate":-0.024036},{"month":11,"riseRate":0.5,"avgChangeRate":0.086142},{"month":12,"riseRate":0.666667,"avgChangeRate":0.131823}],"exchange":"SEHK","name":"云顶新耀","nameEN":"EVEREST MED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"云顶新耀(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供云顶新耀(01952)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"云顶新耀,01952,云顶新耀股票,云顶新耀股票老虎,云顶新耀股票老虎国际,云顶新耀行情,云顶新耀股票行情,云顶新耀股价,云顶新耀股市,云顶新耀股票价格,云顶新耀股票交易,云顶新耀股票购买,云顶新耀股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"云顶新耀(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供云顶新耀(01952)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}